Research at Bristol-Myers Squibb
Research is at the forefront of the drug discovery and development process at Bristol-Myers Squibb. Our goal is to discover novel medicines that will benefit patients with serious unmet medical needs.
We are working towards a strong pipeline of high quality drug candidates, driven by internal research and the external alliances and partnerships that make up our ‘String of Pearls’ strategy.
Research begins with the identification and validation of new biological targets involved in disease processes by using screening technologies to discover candidate compounds that can modulate the target and change the pathological process. Promising candidate compounds (both small molecules and biologics) undergo drug design and optimisation before entering non-clinical safety testing. In addition to understanding potential toxicity issues of all drug candidates, metabolism and pharmaceutical acceptability are studied and structural alterations are made by medicinal chemists striving to produce candidate drugs with favourable benefit/risk profiles.
Our early development group conducts studies to characterise the profile of a new medicine in the human body. The first studies in humans establish how the new medicine is absorbed and distributed by the body. A viable dosage is established and side effects are monitored. We also study pharmacological profiles for all phases of clinical research. Medical care is becoming increasingly more personalised as our understanding of diseases at the molecular level has advanced, and we use advanced technologies to identify biomarkers, and develop assays for the use of these biomarkers in clinical studies.
Scientific innovation is a keystone of our culture, and this is incorporated into all our efforts. In BMS Research we have world class scientific expertise in both disease areas and technology platforms. We welcome motivated, innovative, curious scientists who enjoy working in diverse collaborative teams to achieve Bristol-Myers Squibb’s mission to develop and deliver drug therapies to help patients prevail over serious unmet medical needs
Date of preparation: May 2015 MLTUK1500052-03